Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15458984 | 0.84 | — | — | |
| SCHEMBL15459316 | 0.84 | SREBF1 (0.33) | — | |
| SCHEMBL23802158 | 0.82 | ALDH1A1 (0.32) | GABRA1GABRB2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3654667 | 0.81 | ALDH1A1 (0.39) | ALDH1A1LMNASMN1; SMN2CNR1CNR2 | |
| SCHEMBL23802251 | 0.76 | ALDH1A1 (0.34) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL23801952 | 0.75 | ALDH1A1 (0.32) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL23801983 | 0.75 | CYP19A1 (0.33) | GABRA1GABRB2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL23801957 | 0.74 | CNR2 (0.39) | GABRA1GABRB2ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL23801999 | 0.74 | HMGCR (0.30) | — | |
| SCHEMBL23801948 | 0.73 | RARA (0.32) | ALDH1A1LMNASMN1; SMN2CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284638-A1 | ALPHAvBETA1 INTEGRIN ANTAGONISTS | SAINT LOUIS UNIVERSITY (US) | 2021-09-16 | — | — | US | disclosed |
| US-20210284638-A1 | ALPHAvBETA1 INTEGRIN ANTAGONISTS | SAINT LOUIS UNIVERSITY (US) | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284638-A1 | ALPHAvBETA1 INTEGRIN ANTAGONISTS | ITGB1, ITGAV, ITGA1 | GABRA1 341/4885GABRB2 476/4885ALDH1A1 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.